All In Biotech

Drug Trial Radar · NCT05649761

A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors

A Phase I, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of QL1604, a Humanized Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

61

Planned (sponsor's estimate)

Start

May 29, 2019

Primary completion

Jul 10, 2020

Study completion Jan 23, 2023

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human (FIH), dose-escalation, PK expansion, monotherapy efficacy expansion, and open-label phase I clinical study assessing the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of QL1604 injection (a humanized anti-PD-1 monoclonal antibody)in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • QL1604 injectionDrug

    Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: Up to 21 days after the first dose
  2. maximum tolerated dose(MTD)Time frame: Up to 21 days after the first dose
  3. recommended phase II dose (RP2D)Time frame: up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital of The University of Chinese Academy of Sciences

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.